|
Gene: ARHGEF16 |
Gene summary for ARHGEF16 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARHGEF16 | Gene ID | 27237 |
Gene name | Rho guanine nucleotide exchange factor 16 | |
Gene Alias | GEF16 | |
Cytomap | 1p36.32 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | B3KTS4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27237 | ARHGEF16 | LZE4T | Human | Esophagus | ESCC | 3.44e-02 | 4.36e-02 | 0.0811 |
27237 | ARHGEF16 | LZE8T | Human | Esophagus | ESCC | 5.63e-11 | 3.21e-01 | 0.067 |
27237 | ARHGEF16 | LZE20T | Human | Esophagus | ESCC | 2.23e-02 | 2.15e-01 | 0.0662 |
27237 | ARHGEF16 | LZE22T | Human | Esophagus | ESCC | 4.36e-02 | 4.34e-01 | 0.068 |
27237 | ARHGEF16 | LZE24T | Human | Esophagus | ESCC | 1.61e-05 | 5.04e-02 | 0.0596 |
27237 | ARHGEF16 | P1T-E | Human | Esophagus | ESCC | 3.21e-06 | 3.09e-01 | 0.0875 |
27237 | ARHGEF16 | P2T-E | Human | Esophagus | ESCC | 7.94e-19 | 3.38e-01 | 0.1177 |
27237 | ARHGEF16 | P4T-E | Human | Esophagus | ESCC | 5.14e-14 | 4.25e-01 | 0.1323 |
27237 | ARHGEF16 | P5T-E | Human | Esophagus | ESCC | 3.56e-08 | 1.47e-01 | 0.1327 |
27237 | ARHGEF16 | P8T-E | Human | Esophagus | ESCC | 6.66e-23 | 3.32e-01 | 0.0889 |
27237 | ARHGEF16 | P9T-E | Human | Esophagus | ESCC | 2.63e-11 | 1.26e-01 | 0.1131 |
27237 | ARHGEF16 | P10T-E | Human | Esophagus | ESCC | 8.90e-19 | 4.01e-01 | 0.116 |
27237 | ARHGEF16 | P12T-E | Human | Esophagus | ESCC | 3.58e-07 | 1.13e-01 | 0.1122 |
27237 | ARHGEF16 | P15T-E | Human | Esophagus | ESCC | 4.98e-25 | 7.52e-01 | 0.1149 |
27237 | ARHGEF16 | P16T-E | Human | Esophagus | ESCC | 3.71e-13 | 1.96e-01 | 0.1153 |
27237 | ARHGEF16 | P17T-E | Human | Esophagus | ESCC | 3.35e-04 | 2.13e-01 | 0.1278 |
27237 | ARHGEF16 | P20T-E | Human | Esophagus | ESCC | 5.72e-04 | 2.18e-01 | 0.1124 |
27237 | ARHGEF16 | P21T-E | Human | Esophagus | ESCC | 1.17e-10 | 2.54e-01 | 0.1617 |
27237 | ARHGEF16 | P22T-E | Human | Esophagus | ESCC | 2.24e-15 | 2.05e-01 | 0.1236 |
27237 | ARHGEF16 | P23T-E | Human | Esophagus | ESCC | 6.64e-06 | 5.51e-02 | 0.108 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:190437519 | Esophagus | ESCC | regulation of protein localization to cell periphery | 85/8552 | 125/18723 | 3.63e-07 | 5.06e-06 | 85 |
GO:1903076110 | Esophagus | ESCC | regulation of protein localization to plasma membrane | 72/8552 | 104/18723 | 9.74e-07 | 1.23e-05 | 72 |
GO:190547719 | Esophagus | ESCC | positive regulation of protein localization to membrane | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
GO:190437719 | Esophagus | ESCC | positive regulation of protein localization to cell periphery | 47/8552 | 69/18723 | 1.37e-04 | 9.27e-04 | 47 |
GO:190307817 | Esophagus | ESCC | positive regulation of protein localization to plasma membrane | 43/8552 | 62/18723 | 1.38e-04 | 9.35e-04 | 43 |
GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
GO:007265918 | Oral cavity | OSCC | protein localization to plasma membrane | 169/7305 | 284/18723 | 1.69e-12 | 7.21e-11 | 169 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:190547516 | Oral cavity | OSCC | regulation of protein localization to membrane | 105/7305 | 175/18723 | 1.42e-08 | 2.85e-07 | 105 |
GO:190437516 | Oral cavity | OSCC | regulation of protein localization to cell periphery | 78/7305 | 125/18723 | 9.80e-08 | 1.68e-06 | 78 |
GO:190307617 | Oral cavity | OSCC | regulation of protein localization to plasma membrane | 67/7305 | 104/18723 | 1.34e-07 | 2.24e-06 | 67 |
GO:190547716 | Oral cavity | OSCC | positive regulation of protein localization to membrane | 65/7305 | 106/18723 | 2.69e-06 | 3.32e-05 | 65 |
GO:190437716 | Oral cavity | OSCC | positive regulation of protein localization to cell periphery | 43/7305 | 69/18723 | 7.43e-05 | 5.81e-04 | 43 |
GO:190307815 | Oral cavity | OSCC | positive regulation of protein localization to plasma membrane | 39/7305 | 62/18723 | 1.19e-04 | 8.54e-04 | 39 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGEF16 | SNV | Missense_Mutation | c.870N>A | p.Phe290Leu | p.F290L | Q5VV41 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ARHGEF16 | SNV | Missense_Mutation | rs368911182 | c.1766G>A | p.Arg589His | p.R589H | Q5VV41 | protein_coding | tolerated(0.37) | benign(0.009) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARHGEF16 | insertion | Frame_Shift_Ins | novel | c.1551dupT | p.Arg518SerfsTer49 | p.R518Sfs*49 | Q5VV41 | protein_coding | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ARHGEF16 | deletion | In_Frame_Del | rs765928654 | c.893_895delCCT | p.Ser298del | p.S298del | Q5VV41 | protein_coding | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ARHGEF16 | deletion | Frame_Shift_Del | novel | c.1234delN | p.Gly413AlafsTer8 | p.G413Afs*8 | Q5VV41 | protein_coding | TCGA-EY-A548-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ARHGEF16 | SNV | Missense_Mutation | c.1248N>A | p.Met416Ile | p.M416I | Q5VV41 | protein_coding | deleterious(0.02) | possibly_damaging(0.604) | TCGA-38-4629-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ARHGEF16 | SNV | Missense_Mutation | novel | c.1291N>G | p.Pro431Ala | p.P431A | Q5VV41 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-7662-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ARHGEF16 | SNV | Missense_Mutation | rs536938385 | c.1046N>A | p.Arg349Gln | p.R349Q | Q5VV41 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-18-3410-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ARHGEF16 | SNV | Missense_Mutation | novel | c.873G>T | p.Glu291Asp | p.E291D | Q5VV41 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-85-8071-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ARHGEF16 | SNV | Missense_Mutation | novel | c.1475C>G | p.Ser492Cys | p.S492C | Q5VV41 | protein_coding | deleterious(0) | possibly_damaging(0.662) | TCGA-BA-4077-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cetuximab | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |